BASKING RIDGE, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”),
a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select
therapeutic development pipeline, announces today that the Company’s leadership will present at the following upcoming
November conferences:
Sidoti 2016 Emerging Growth Convention
ARM EU Advanced Therapies Investor Day
- Date and Time: Thursday, November 3, 2016, 8:40 AM GMT
-
Website: http://eu.arminvestorday.com/
- Venue: 30 Euston Square, London, England
- Topic: Fireside Chat: Immuno-oncology
- Session Chair: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief
Technology Officer, and Director
Life Sciences Summit 2016
- Date and Time: Thursday, November 3, 2016, 10:00 AM ET
-
Website: http://lifesciencessummit.org
- Venue: Times Warner Center, New York, New York
- Topic: Regenerative Medicine: Will iPS Cells Deliver as Promised?
- Panelist: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief
Medical Officer
American Heart Association Scientific Sessions
Session 1
- Date and Time: Monday, November 14, 2016, 4:15 PM CT
- Topic: Myocyte Preplacement for the Failing Heart
- Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief
Medical Officer
Session 2
- Date and Time: Tuesday, November 15, 2016, 4:30 PM CT
- Topic: Endogenous Pro-Angiogenic Cells and MI
- Presenter: Douglas Losordo, MD, Senior Vice President, Clinical, Medical and Regulatory Affairs, and Chief
Medical Officer
2016 World Alliance Forum in San Francisco
-
Website: http://wafsf.org
- Venue: The Golden Gate Club, San Francisco, California
Session 1
- Date and Time: Monday, November 21, 2016, 9:15 AM PT
- Topic: Overview: Cell & Gene Therapy
- Presenter: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief
Technology Officer, and Director
Session 2
- Date and Time: Tuesday, November 22, 2016, 9:10 AM PT
- Panel: Cell and Gene Therapy & Cancer Immunotherapy - Overview
- Moderator: Robert Preti, PhD, Senior Vice President, Manufacturing and Technical Operations, Chief
Technology Officer, and Director
About Caladrius Biosciences
Caladrius Biosciences, Inc. is advancing a proprietary platform technology for immunomodulation by pioneering the use of T
regulatory cells as an innovative therapy for recent onset type 1 diabetes. The product candidate, CLBS03, is the subject of
an ongoing Phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted
Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration and Advanced Therapeutic Medicinal Product
classification by the European Medicines Agency. The Company’s PCT subsidiary is a leading development and manufacturing
partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy
manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing,
engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and
regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the
creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. For
more information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the
SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and
market acceptance, which are outside of its control.
CONTACTS: Investors: LHA Investor Relations Anne Marie Fields Senior Vice President Phone: +1-212-838-8377 Email: afields@lhai.com Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: epowers@caladrius.com
